ARCHIVES

ODAC Recommends Iressa Approval As Third-Line Lung Cancer Treatment

This article is from The Cancer Letter archive.

Vol. 28 No. 35 | September 27, 2002

Download PDF Visit The Full Archive

Related Articles

FY’78 Construction Requests $44 Million, Budget At $12 Million

December 2, 1977

Lenalidomide Maintenance Increased PFS and Survival

May 25, 2012

Ten Cooperative Group Chairs Propose Eight “Guiding Principles” For Change

May 20, 2011

Cancer Patients Who Die In Hospital Or ICU Have Worse QOL; Caregivers Affected, Too

September 24, 2010

CIS Recompetition Approved, But BSC Delays Decision On Matching Requirement

May 15, 1987

Also in this 8-page issue: FISH assay predicts survival on Iressa, Univ. of Colorado Cancer Center study finds.

May 6, 2005